POLB
NEUTRALPoolbeg Pharma Granted European Patent for POLB 001
The biopharmaceutical company has been granted a European patent for its lead asset POLB 001, further strengthening its intellectual property portfolio.
Poolbeg Pharma
3.6500GBX
0.00%
Market Cap
25.45M
Volume
466.39k
35% of avg
P/E Ratio
-3.07
EPS (TTM)
-1.19
Beta
2
Day Range
3.6110p - 3.8000p
52 Week Range
2.2500p3.6500p7.7000p
3.6500p
Upcoming Events
POLB
NEUTRALPoolbeg Pharma Reports Progress in Clinical Trials and Extended Cash Runway
The clinical-stage biopharmaceutical firm reported progress in its drug development programs and an extended cash runway, while still navigating the challenges of pre-revenue operations and ongoing losses.
POLB
NEUTRALPoolbeg Pharma Advances POLB 001 Phase 2a Trial
The biopharmaceutical company has signed an agreement to conduct a Phase 2a trial for its lead asset POLB 001, which aims to reduce the risk of a life-threatening side effect in cancer immunotherapy treatments.
POLB
NEUTRALPoolbeg Pharma Announces Director Dealings
The healthcare company has announced a change in major shareholder holdings.
POLB
NEUTRALPoolbeg Pharma Announces Major Shareholder Disclosure
The healthcare company has received notification of a major shareholder holding in the business.
POLB
NEUTRALPoolbeg Pharma Chair Increases Stake
The prominent biopharmaceutical company has announced that its Executive Chair has purchased additional shares in the business.
POLB
NEUTRALPoolbeg Pharma Receives FDA Orphan Drug Designation for POLB 001
The biopharmaceutical company has received Orphan Drug Designation from the FDA for its POLB 001 drug candidate, which is being developed as a preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome.
POLB
NEUTRALPoolbeg Pharma Releases Annual Report and AGM Notice
The biopharmaceutical company has released its annual report and notice of the upcoming annual general meeting.
POLB
NEUTRALPoolbeg Pharma Raises £150,000 in Oversubscribed Bookbuild Offer
The biopharmaceutical company has conditionally raised £150,000 through an oversubscribed bookbuild offer, with the funds to be used for advancing its clinical pipeline.
POLB
GOODPoolbeg Pharma Increases BookBuild Offer to Raise £150,000
The biopharmaceutical company is increasing its BookBuild Offer to raise £150,000 to fund the advancement of its clinical pipeline, including trials for a cancer immunotherapy and an oral GLP-1 program.